Who
Neil F. McFarlane
President and CEO
Company insider
Files Form 4 as: President and CEO, Zevra Therapeutics; Director, Collegium Pharmaceutical; Chief Executive Officer, Adamas Pharmaceuticals; Chief Operating Officer, Travere Therapeutics.
In numbers
- Trades disclosed
- 60
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $3.7M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 15 Aug 2016
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $225K20,000 at $11.25 | filing |
| 10 Oct 2026filed 13 Oct 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —50,000 | filing |
| 10 Oct 2026filed 13 Oct 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K14,625 at $8.56 | filing |
| 9 Feb 2026filed 10 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K14,625 at $8.56 | filing |
| 7 Feb 2026filed 10 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —37,500 | filing |
| 7 Feb 2026filed 10 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 7 Feb 2026filed 10 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —37,500 at $0.00 | filing |
| 7 Feb 2026filed 10 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —37,500 | filing |
| 2 Feb 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $853K91,000 at $9.38 | filing |
| 2 Feb 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $854K91,000 at $9.38 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —233,334 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —233,334 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —233,334 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —233,334 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 10 Oct 2025filed 10 Oct 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.